Oxygen Therapy Options in LA
Los Angeles has become a hub for advanced oxygen-based therapies, with clinics offering multiple modalities for conditions ranging from chronic fatigue and neurological decline to wound healing and athletic recovery. The problem is not availability but understanding. Three distinct therapies, KureO2 Oxygen Immersion, Hyperbaric Oxygen, and Ozone Therapy, are often discussed as if they are interchangeable. They are not. Each uses a fundamentally different mechanism to deliver oxygen or oxygen-derived molecules, and each has different clinical applications, different risk profiles, and different levels of evidence.
The confusion benefits no one. A patient who needs the dissolved plasma oxygen that KureO2 provides may waste months in a hyperbaric chamber that does not achieve the same tissue saturation. A patient who needs the immune modulation of ozone therapy may not benefit from hyperbaric pressure. The wrong therapy is not just ineffective. It consumes time, money, and the patient's willingness to continue seeking care.
Understanding the mechanism of each therapy allows informed decisions about which approach matches the clinical need. The physics of how oxygen reaches cells determines which conditions each therapy addresses effectively. Pressure-driven oxygen delivery works differently than plasma-dissolved oxygen, which works differently than oxidative stress signaling from ozone.
At Kure Health, oxygen therapy selection is based on the VITAL Index assessment and the specific clinical indication. KureO2 is the primary modality for conditions requiring maximum plasma oxygen delivery, while hyperbaric and ozone protocols may be recommended when their specific mechanisms match the clinical need. The goal is not to sell a therapy. It is to match the right mechanism to the right condition.
KureO2: How It Works
KureO2 Oxygen Immersion Therapy is Kure Health's proprietary oxygen delivery system based on technology widely used in European clinical settings. The mechanism is direct: blood is drawn through a closed-loop extracorporeal circuit, exposed to medical-grade oxygen under controlled conditions, and returned to the body with oxygen dissolved directly into the plasma fraction at concentrations that normal breathing and even hyperbaric environments cannot achieve.
The critical distinction is between hemoglobin-bound oxygen and plasma-dissolved oxygen. Under normal conditions, hemoglobin carries approximately 98 percent of blood oxygen and the plasma carries the remaining 2 percent. Hemoglobin saturation has a ceiling: at normal atmospheric pressure, hemoglobin is already 95 to 99 percent saturated. Breathing more oxygen cannot significantly increase what hemoglobin carries. Plasma-dissolved oxygen has no such ceiling and can be increased dramatically.
Plasma-dissolved oxygen reaches tissues that hemoglobin-bound oxygen cannot efficiently access. It crosses the blood-brain barrier more readily. It perfuses compromised tissue where capillary damage prevents red blood cell delivery. It reaches the interior of tumors, biofilms, and injured tissue where reduced blood flow limits hemoglobin-transported oxygen. For clinical conditions involving tissue hypoxia, impaired microcirculation, or blood-brain barrier relevant pathology, plasma oxygen delivery is the relevant metric.
A KureO2 session typically lasts 45 to 60 minutes. The procedure is minimally invasive, conducted in a clinical setting with continuous monitoring. Most patients report immediate increased mental clarity, improved energy, and a subjective sense of oxygenation that persists for hours to days after the session. Treatment protocols typically involve serial sessions tailored to the clinical indication.
Hyperbaric Oxygen: Pressurized Chambers
Hyperbaric Oxygen Therapy delivers oxygen at pressures greater than atmospheric, typically 1.5 to 3 atmospheres absolute, while the patient breathes 100 percent oxygen inside a pressurized chamber. The physics are based on Henry's Law: the amount of gas dissolved in a liquid is proportional to the partial pressure of that gas above the liquid. At 2 ATA breathing pure oxygen, plasma dissolved oxygen increases approximately 10-fold compared to atmospheric conditions.
HBOT has established clinical evidence for specific conditions including decompression sickness, carbon monoxide poisoning, diabetic wound healing, radiation tissue injury, compromised skin grafts, and certain infections including gas gangrene and necrotizing fasciitis. These are FDA-cleared indications with substantial evidence supporting the use of pressurized oxygen delivery for tissue repair and infection control.
The limitations of HBOT include practical and physiological constraints. Treatment sessions last 60 to 120 minutes in a chamber that some patients find claustrophobic. Pressure changes carry risks including barotrauma to the ears and sinuses, and in rare cases, oxygen toxicity seizures at higher pressures. The oxygen delivery, while significantly above atmospheric, still relies partly on hemoglobin transport because the patient is breathing the oxygen rather than having it dissolved directly into plasma.
Soft-shell hyperbaric chambers available in wellness settings operate at 1.3 to 1.5 ATA, well below the pressures used in clinical HBOT. The evidence supporting these lower-pressure treatments is substantially weaker than for clinical HBOT, and the plasma oxygen increases achieved are correspondingly smaller. Patients considering hyperbaric therapy should distinguish between clinical HBOT at medical facilities and low-pressure wellness treatments.
Ozone Therapy: O3 Applications
Ozone therapy uses O3, a triatomic form of oxygen, to stimulate a controlled oxidative stress response in the body. Unlike KureO2 and HBOT, which aim to increase oxygen delivery to tissues, ozone therapy works primarily through signaling: the brief oxidative stress from ozone exposure activates the body's antioxidant defense systems, modulates immune function, and stimulates cellular repair pathways. The mechanism is hormetic, meaning the controlled stress produces an adaptive beneficial response.
The most common delivery method is Major Autohemotherapy, where blood is drawn, mixed with ozone gas, and reinfused. Other delivery methods include rectal insufflation, where ozone gas is introduced into the colon for systemic absorption, and localized ozone application for wound treatment and infection control. Each route provides different concentrations and distribution patterns.
The clinical applications of ozone therapy are primarily immunomodulatory and antimicrobial. Ozone has documented activity against bacteria, viruses, and fungi, and has been used in European and South American clinical settings for chronic infections, autoimmune conditions, and immune deficiency. It is not primarily an oxygen delivery therapy, and patients seeking tissue oxygenation may be better served by KureO2 or HBOT.
The regulatory landscape for ozone therapy in the United States is complex. The FDA has not approved ozone for medical treatment, although it is practiced under physician oversight in many states. The evidence base is growing but remains less robust than HBOT for most indications. At Kure Health, ozone therapy is available when the clinical indication specifically calls for immune modulation or antimicrobial effect, and it is not positioned as a substitute for direct oxygen delivery therapies.
Head-to-Head: When to Use What
The selection between KureO2, HBOT, and ozone depends entirely on the clinical objective. KureO2 is indicated when the goal is maximum plasma oxygen delivery: chronic fatigue with mitochondrial dysfunction, neurological conditions requiring blood-brain barrier oxygen penetration, chronic wound healing where microcirculation is compromised, post-surgical recovery, and athletic performance optimization. KureO2 achieves plasma oxygen levels that exceed both atmospheric and hyperbaric delivery without pressure-related risks.
HBOT is indicated when established FDA-cleared indications are present: decompression illness, carbon monoxide poisoning, radiation tissue injury, specific wound types, and compromised surgical grafts. Clinical HBOT at appropriate pressures has strong evidence for these specific conditions. For conditions outside these established indications, the evidence is variable and the practical constraints of chamber-based treatment may limit patient compliance.
Ozone therapy is indicated when immune modulation is the primary objective: chronic viral reactivation including EBV and herpes family viruses, chronic bacterial infections particularly in biofilm-forming organisms, autoimmune conditions requiring immune rebalancing, and adjunctive cancer support for immune enhancement. The mechanism is different from oxygen delivery, and the clinical targets are correspondingly different.
At Kure Health, therapy selection is integrated into the VITAL Index treatment protocol. A patient with chronic fatigue may receive KureO2 for tissue oxygenation alongside ozone for immune modulation if testing reveals both mitochondrial dysfunction and chronic viral reactivation. The therapies are complementary when the clinical indications overlap, and the comprehensive assessment ensures that each therapy is applied where its mechanism provides the greatest benefit.
